Transcode Therapeutics Inc
Change company Symbol lookup
Select an option...
RNAZ Transcode Therapeutics Inc
IRM Iron Mountain Inc
BKU BankUnited Inc
TGB Taseko Mines Ltd
AB AllianceBernstein Holding LP
LIQT LiqTech International Inc
ITCI Intra-Cellular Therapies Inc
OPBK OP Bancorp
LUVU Luvu Brands Inc
FINV FinVolution Group
Go

Health Care : Biotechnology |
Company profile

TransCode Therapeutics, Inc. is a ribonucleic acid (RNA) oncology company. The Company's lead therapeutic candidate, TTX-MC138, is focused on treating metastatic cancer. TTX-MC138 comprises proprietary iron-oxide nanoparticles and oligonucleotides that specifically target microRNA-10b. The nanoparticles serve as the vehicle to deliver oligonucleotides to metastatic cancer cells. The magnetic properties of these nanoparticles allow for monitoring of their delivery using non-invasive imaging. Its pipeline products also include TTX-siPDL1, TTX-siLIN28b and TTX-RIGA. TTX-siPDL1 is a checkpoint inhibitor targeting programmed cell death protein ligand 1 (PD-L1). TTX-RIGA utilizes its delivery system and is intended to activate the RIG-I signaling pathway to elicit an immune response to eliminate and/or reduce the risk of developing disorders associated with abnormal apoptotic or differentiative processes, by triggering an immune response that targets developing cancer cells.

Closing Price
$2.92
Day's Change
0.23 (8.55%)
Bid
--
Ask
--
B/A Size
--
Day's High
2.99
Day's Low
2.71
Volume
(Above Average)
Volume:
88,385

10-day average volume:
79,368
88,385

Bank of America shuts down bank account of FDA-approved cannabis research firm

3:01 pm ET October 21, 2021 (MarketWatch)
Print

Steve Gelsi

Cannabis banking remains illegal under federal law, although this program was OK'd by the FDA

Bank of America has notified the Scottsdale Research Institute that it will close its bank account next month, even though the firm's cannabis research has been sanctioned by the federal government.

In an Oct. 12 letter to the Scottsdale Research Institute that was posted on social media, Bank of America (BAC) said it would restrict banking services in 21 days and permanently close it by Nov. 12 and that the "decision is final" and won't be reconsidered.

"Bank of America closes down account of Federally-licensed cannabis researcher," Dr. Sue Sisley said on her Twitter page on Friday. "SRI conducts FDA approved controlled trials evaluating cannabis as medicine for treating pain/PTSD in military veterans & terminally ill patients this TRAGICALLY shuts down our research."

At last check, the tweet drew 55 comments, mostly criticizing Bank of America. Some people said they would cancel their credit cards with the bank.

A spokesperson for the bank that MarketWatch contacted did not comment.

Sisley, a psychiatrist and president of Scottsdale Research Institute (SRI), included in her tweet a photo of her Controlled Substance Registration Certificate from the U.S. Drug Enforcement Administration. The SRI won the designation this year after a legal battle with the U.S. government for the right to produce cannabis for medical testing.

Scottsdale Research Institute is currently reviewing bids from other financial institutions, according to an article by cannabis publication Marijuana Moment.

"We just wanted to expose wrongdoing of these big banks," Sisley told the publication. The Scottsdale Research Institute wants to publicize that even federally legal operations are being targeted by these large banks who refuse to look at its federal regulatory documents, she said.

Sisley speculated that publicity around Scottsdale Research Institute's addition of psychoactive mushrooms, or psilocybin, to its research may have prompted the bank's action but the bank provided "zero justification."

The firm has been upfront with Bank of America for 10 years about its use of cannabis. It originally used cannabis from the University of Mississippi for its studies but then won the right to cultivate its own marijuana.

"We have a contract with DEA. We are growing cannabis for [Food and Drug Administration] clinical trials and selling it to the DEA," she said in the article by Marijuana Moment. "It's unconscionable the way they are behaving--and further proof that the word 'cannabis' continues to be completely radioactive even though this is a 100% federally legal operation."

Sisley was fired from University of Arizona in 2014 after she received approval from federal drug officials to study the effects of pot on patients suffering from post-traumatic stress disorder.

Meanwhile, cannabis remains on the federal government's list of controlled substances, which prevents cannabis-related businesses from using the banking system in many cases. Some banks have been serving cannabis companies under banking guidelines published during the Obama administration, but the U.S.'s largest institutions continue to avoid any businesses or organizations that touch the plant.

Meanwhile, the SAFE banking act to potentially open up the banking system to cannabis remains in limbo in the U.S. Senate after recently winning passage in the U.S. House of Representatives. Cannabis pundits do not expect any major moves out of Congress in the near future.

See Also:Cannabis sector is not banking on help from Congress before 2022

-Steve Gelsi

	

(END) Dow Jones Newswires

October 21, 2021 15:01 ET (19:01 GMT)

Copyright (c) 2021 Dow Jones & Company, Inc.

Earnings Calendar and Events Data provided by |Terms of Use| © 2021 Wall Street Horizon, Inc.

Market data accompanied by is delayed by at least 15 minutes for NASDAQ, NYSE MKT, NYSE, and options. Duration of the delay for other exchanges varies.
Market data and information provided by Morningstar.

Options are not suitable for all investors as the special risks inherent to options trading may expose investors to potentially rapid and substantial losses.
Please read Characteristics and Risks of Standard Options before investing in options.

Information and news provided by ,, , Computrade Systems, Inc., ,, and

Copyright © 2021. All rights reserved.